Circulating Endoglin Levels in Chronic Kidney Disease
Author Information
Author(s): Charytan David M., Helfand Alexander M., MacDonald Brian A., Cinelli Angeles, Kalluri Raghu, Zeisberg Elisabeth M.
Primary Institution: Brigham and Women's Hospital, Boston, Massachusetts, United States of America
Hypothesis
Elevations in the concentration of circulating endoglin in CKD could contribute to the progression of CKD and underlie the association of CKD and cardiovascular disease.
Conclusion
Renal function is not associated with the circulating concentration of soluble endoglin, suggesting that increases in endoglin levels are unlikely to contribute to CKD progression or cardiovascular disease risk.
Supporting Evidence
- Serum endoglin concentration did not vary significantly with CKD stage.
- Endoglin concentration was not higher in individuals with ESRD than in those with preserved renal function.
- The study included 216 patients, with 118 having stage 3 or higher CKD.
Takeaway
This study looked at a protein called endoglin in people with kidney disease and found that it doesn't increase as kidney function worsens, which means it likely doesn't cause heart problems in these patients.
Methodology
The study measured serum endoglin concentration in individuals with and without CKD and analyzed the association with eGFR and CKD stage using regression models.
Potential Biases
The single-center design may limit the generalizability of the findings.
Limitations
The study was limited by the inability to measure GFR directly and the small number of individuals with ESRD.
Participant Demographics
Participants were aged 18-80, with a mix of genders and races, recruited from a single center.
Statistical Information
P-Value
0.09
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website